Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cannara Biotech Inc (OP: LOVFF )

0.5055 -0.0360 (-6.65%)
Streaming Delayed Price Updated: 3:51 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,700
Open 0.4924
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.5415
Today's Range 0.4747 - 0.5100
52wk Range 0.3971 - 0.7750
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Canadian Cannabis Producer Cannara Reports 43% YoY Revenue Growth, Boosts Market Share And Profitability
Vertically integrated cannabis producer Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0) announced on Monday its fourth quarter and full fiscal 2024 financial and operating results ended... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire

Performance

YTD
-19.07%
-19.07%
1 Month
-1.10%
-1.10%
3 Month
-5.90%
-5.90%
6 Month
-9.25%
-9.25%
1 Year
-22.43%
-22.43%

More News

Read More
Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports Q3 2024 Financial Results
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannabis Slowdown In Canada: Analyst Spotlights What Still Sells And Where The Money Is Going
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss
Via Benzinga
Topics Cannabis
Exposures Cannabis
This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
Via News Direct
Topics Cannabis
Exposures Cannabis
The 7 Most Undervalued Cannabis Stocks to Buy in December
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
Via Benzinga
Topics Cannabis
Exposures Cannabis
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
7 Smoking-Hot 420 Stocks to Buy in 2023
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For August 10, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Q3 FY23 Net Revenue Grows 57% YoY, What About Adjusted EBITDA?
Via Benzinga
Cannabis Stock Gainers And Losers From July 25, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 4, 2023
Via Benzinga
Cannara Biotech Secures An Additional $10M In Non-Dilutive Capital With Its Lead Credit Provider, BMO Commercial Banking
Via Benzinga
Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details
Via Benzinga
Marijuana Stock Movers For August 1, 2023
Via Benzinga
Olymbec Investments Increases Its Ownership In Cannara Biotech
Via Benzinga
Cannara Biotech Q1 Revenue Grows 57% YoY To $7.7M, What About Adjusted EBITDA?
Via Benzinga
Cannabis Stock Movers For July 27, 2023
Via Benzinga
Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M
Via Benzinga
Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products
Via Benzinga
Cannara Biotech Signs An Exclusive Brand Partnership With Exotic Genetix In Canada
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.